The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation

Due to the widespread use of tyrosine kinase inhibitors (TKIs), which have largely supplanted cytotoxic chemotherapy as the first-line therapeutic choice for patients with advanced non-small cell lung cancer (NSCLC) who have oncogene driver mutations, advanced NSCLC patients with oncogene driver mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Jinfeng, Li, Li, Yuan, Shuanghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139486/
https://www.ncbi.nlm.nih.gov/pubmed/35646640
http://dx.doi.org/10.3389/fonc.2022.863715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139486/
https://www.ncbi.nlm.nih.gov/pubmed/35646640
http://dx.doi.org/10.3389/fonc.2022.863715

Ejemplares similares